Clinical Utility of Fluorescence in-situ Hybridization Profile Test in Detecting Genetic Aberrations in Acute Leukemia.
10.3343/kjlm.2009.29.5.371
- Author:
Suk Ran KIM
1
;
Hee Jin KIM
;
Sun Hee KIM
Author Information
1. Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. sunnyhk@skku.edu
- Publication Type:Original Article ; English Abstract
- Keywords:
Acute leukemia;
Cytogenetic analysis;
Fluorescence in-situ hybridization
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
*Chromosome Aberrations;
Core Binding Factor Alpha 2 Subunit/genetics;
Core Binding Factor beta Subunit/genetics;
Cyclin-Dependent Kinase Inhibitor p16/genetics;
Female;
Humans;
In Situ Hybridization, Fluorescence/*methods;
Infant;
Infant, Newborn;
Karyotyping;
Leukemia, Myeloid, Acute/*diagnosis/genetics;
Male;
Middle Aged;
Myeloid-Lymphoid Leukemia Protein/genetics;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/genetics;
Proto-Oncogene Proteins c-bcr/genetics
- From:The Korean Journal of Laboratory Medicine
2009;29(5):371-378
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Cytogenetic abnormalities are one of the most reliable prognostic factors in acute leukemia. Combination of conventional chromosome analysis (CCA) and FISH provides higher sensitivity in detecting these genetic abnormalities, and it is effective to apply several FISH probes as a profile test. The objective of this study was to investigate the utility of FISH profile analyses in the initial diagnosis of acute leukemia. METHODS: Two hundred and forty one de novo acute leukemia patients diagnosed from January, 2002 to November, 2007 were included. For acute lymphoblastic leukemia profile test, FISH probes for BCR/ABL, TEL/AML1, MLL gene rearrangement and CDKN2A deletion were used. For acute myeloid leukemia profile test, probes for AML1/ETO, MLL and CBFbeta gene rearrangement were used. The results of CCA and FISH profile tests were collected, and the positive rates were compared. RESULTS: ALL FISH profile tests revealed additional genetic aberrations not detected by chromosome analysis in 48.6% (67/138) of cases, including those with normal karyotypes or no mitotic cells (37%, 51/138). Among these 51 cases, TEL/AML1 abnormalities were detected in 44.3%, followed by the abnormal CDKN2A signal (24.6%) and hyperdiploidy (18.0%). AML FISH profile tests revealed additional genetic abnormalities in 7.8% (8/103) of cases. CONCLUSIONS: FISH analysis as a profile test detected additional genetic aberrations in a significant proportion of acute leukemia, and was effective especially in detecting cryptic translocations, submicroscopic deletions and complex karyotypes. Our study supports the need to incorporate FISH profile test at initial work up in acute leukemia.
